HMDCF — HUTCHMED (China) Ltd
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1648257 ·
Hong Kong
Last close
$2.16
Market Cap
$1.88B
52W High
$3.66
52W Low
$2.16
ADV30
0
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Dec 2025 | — | — | — | — | 1,753,097,000 | 71,330,000 | 501,835,000 |
| Jun 2025 | — | — | — | — | 1,775,940,000 | — | 534,017,000 |
Balance + Analyst (yfinance extras)
Retained Earnings
$-378,643,000
Inventory
$41,129,000
Receivables
—
ST Investments
$1,295,945,000
EBIT TTM
—
Pretax Income TTM
—
Interest Exp TTM
—
Analysts
—
Yahoo Snapshot (yfinance, live)
Total Revenue
$549,121,984
EBITDA
$-20,515,000
Free Cash Flow
$-18,880,250
Enterprise Value
$609,436,992
Total Cash
$1,376,455,936
Total Debt
$94,508,000
Shares Out
869,070,839
Trailing EPS
$0.02
Book Value
$1.45
ROE
1.5%
ROA
-1.2%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 548,512,000 | -35,700,000 | 456,909,000 | 1,750,000,000 | 502,000,000 | 1,237,926,000 | -64,657,000 |
| Dec 2024 | 630,201,000 | -40,610,000 | 37,729,000 | 1,270,000,000 | 502,343,000 | 759,929,000 | 497,000 |
| Dec 2023 | 837,999,000 | 21,509,000 | 100,780,000 | 1,280,000,000 | 536,386,000 | 730,541,000 | 219,258,000 |
| Dec 2022 | 426,409,000 | -406,259,000 | -360,835,000 | 1,030,000,000 | 392,575,000 | 610,367,000 | -268,599,000 |
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ZBIO | Zenas BioPharma, Inc. | $1.88B | $27.75 | — |
| VERA | Vera Therapeutics, Inc. | $1.89B | $26.20 | — |
| SEPN | Septerna, Inc. | $1.90B | $40.02 | — |
| ETON | Eton Pharmaceuticals, Inc. | $1.84B | $63.65 | — |
| TRAX | First Tracks Biotherapeutics, Inc. | $1.83B | $43.57 | — |
News headlines (Yahoo Finance, 1h cache)
HUTCHMED Highlights HMPL-A830 Pre-Clinical Data Presented at the 38th EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics
2026-11-19 00:00 · Yahoo
HUTCHMED (AIM:HCM) Stock Looks Overvalued On Current Earnings
2026-11-17 21:15 · Yahoo
HUTCHMED Announces Expanded Coverage on National Reimbursement Drug List for ELUNATE® and ORPATHYS®
2026-11-16 04:00 · Yahoo
3 British Healthcare Stocks With Revenue Growth Up To 13%
2026-11-14 03:12 · Yahoo
UPDATE – International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on November 12, 2026
2026-11-09 16:56 · Yahoo
UK Stock Market Today: FTSE 100 Futures Slip On Housing Weakness And Data Watch
2026-11-09 07:08 · Yahoo
Should Phase III Lung Cancer Data Require Action From Hutchmed (AIM:HCM) Investors?
2026-11-08 09:11 · Yahoo
British Healthcare Stocks To Watch In November 2026
2026-11-07 02:15 · Yahoo
HUTCHMED (China) (AIM:HCM) Extends Lung Cancer Filing Run As Undervalued View Holds
2026-11-06 01:21 · Yahoo
International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on November 12, 2026
2026-11-05 13:35 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.